Please ensure Javascript is enabled for purposes of website accessibility

Why Biogen Inc.'s Stock Sank in January

By George Budwell - Feb 11, 2016 at 11:59AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Biogen's slowing growth has investors looking towards the future.

BIIB Chart

What: Shares of the biotech giant Biogen (BIIB 1.60%) fell by more than 11% last month, according to data provided by S&P Global Market Intelligence. The drugmaker's monthly tumble was due to the downturn among all-things biotech, along with the domestic sales of its top-selling multiple sclerosis drug Tecfidera leveling off in recent quarters. 

So what: Biogen is one of the largest holdings of the iShares Nasdaq Biotechnology ETF (IBB -0.02%), making it a key name to watch in terms of the market's sentiment regarding biotechs at large. After all, Biogen's poor showing last month probably contributed significantly to the IBB's January blues:

IBB Chart

Now what: With Biogen's top-line expected to grow by a modest 6% this year, the market's focus is likely to turn toward the biotech's clinical activities moving forward. The good news is that Biogen is planning on plowing roughly 20% of its total revenues into R&D this year in hopes of kick-starting its growth engine. 

Among the biotech's more noteworthy clinical activities, Biogen and its partner Ionis Pharmaceuticals are reportedly making steady progress with their late-stage experimental treatment, nusinersen, for spinal muscular atrophy that might result in an accelerated regulatory filing sometime soon. Regardless, this collaboration should start to produce top-line data readouts in the first half of 2017, possibly leading to Biogen's next major new drug. 

Although Biogen probably won't turn in a great 2016 in terms of its share-price performance, I think the stock remains a compelling buy longer term because of the company's emerging clinical pipeline that sports potentially groundbreaking new drugs like aducanumab for Alzheimer's disease and, of course, nusinersen for spinal muscular atrophy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$215.98 (1.60%) $3.40
Ionis Pharmaceuticals, Inc. Stock Quote
Ionis Pharmaceuticals, Inc.
IONS
$36.81 (-2.75%) $-1.04
iShares Trust - iShares Nasdaq Biotechnology ETF Stock Quote
iShares Trust - iShares Nasdaq Biotechnology ETF
IBB
$122.79 (-0.02%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
323%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.